Adenoviral (AdV) and Adenovirus-associated viral (AAV) vectors both are used for in vivo gene therapy of inherited liver disorders, such as Crigler-Najjar syndrome type 1. In a relevant animal model, the Gunn rat, both vectors efficiently correct the severe hyperbilirubinemia characteristic of this liver disorder. Although the clinical use of AAV is more advanced, as demonstrated by the successful phase 1 trial in hemophilia B patients, because of its large cloning capacity AdV remains an attractive option. A direct comparison of the efficacy of these two vectors in the liver in a relevant disease model has not been reported. Aim of this study was to compare the efficiency of clinically applicable doses of both vectors in the Gunn rat. AdV or scAAV (self-complimentary AAV) ferrying identical liver-specific expression cassettes of the therapeutic gene, UGT1A1, were injected into the tail vein. As the titration methods of these two vectors are very different, a comparison based on vector titers is not valid. Therefore, their efficacy was compared by determining the amount of vector genomes delivered to the liver required for therapeutic correction of serum bilirubin. Like AAV, the liver-specific first-generation AdV also provided sustained correction in this relevant disease model. UGT1A1 mRNA expression provided per genome was comparable for both vectors. Flanking the expression cassette in AdV with AAV-ITRs (inverted terminal repeats), increased UGT1A1 mRNA expression eightfold which resulted in a significant improvement of efficacy. Compared with AAV, less AdV genomes were needed for complete correction of hyperbilirubinemia.
INTRODUCTION
Crigler-Najjar syndrome, inherited severe unconjugated hyperbilirubinemia, is caused by deficiency of the hepatic UDP (uridine diphosphate)-glucuronosyltransfererase 1A1 (UGT1A1). This severe potentially lethal disorder is an attractive candidate for the development of in vivo liver-directed gene therapy as it does not affect liver architecture nor causes liver damage. 1 It is well characterized both at the biochemical and molecular level while intensive phototherapy can prevent irreversible neurological damage until gene therapy treatment becomes possible. In addition, restoring only about 5% of the normal UGT1A1 activity will lower serum bilirubin enough to minimize the risk on brain damage allowing patients to stop the cumbersome phototherapy. [2] [3] [4] Furthermore, monitoring treatment efficacy is straightforward by quantification of total bilirubin in serum and bilirubin conjugates in bile. Finally, a relevant well-characterized pre-clinical animal model, the Gunn rat, is available. Adenoviral (AdV) and Adeno-associated viral (AAV) vectors both are potential candidates for in vivo liver-directed gene therapy via systemic administration. As both persist in an extra-chromosomal (episomal) form, these vectors are less suitable for corrective gene therapy in proliferating tissues. 5, 6 In the liver, which normally is quiescent, sustained therapeutic correction can be provided by both. [7] [8] [9] As such, these two vectors are potential candidates for corrective gene therapy in Crigler-Najjar patients and their efficacy has been explored in the Gunn rat.
AdV vectors expressing UGT1A1 do provide complete correction of hyperbilirubinemia in the Gunn rat. Although initially efficacy was lost within months, 10 with the novel so called helper-dependent (or gutless) AdV vectors (HDAd) life-long correction is obtained. 11 The strong innate immune response towards this vector, however, remains a hurdle and renders dose reduction essential for its use in patients. In a recent study, therapeutic correction of hyperbilirubinemia is obtained in the Gunn rat upon systemic injection of 5 Â 10 11 viral particles per kilogram (vp kg À 1 ) of HDAd, a dose that seems low enough to be applied in patients suffering from Crigler-Najjar syndrome. 12 A major advantage of AAV compared with AdV is its lower innate immune response. 13 The recent successful correction of factor IX deficiency in hemophila B patients underscores the clinical potential of this vector.
14 Previously, we showed that in the Gunn rat sustained correction of hyperbilirubinemia is obtained with several AAV serotypes. 15 In that study, a dose of 2 Â 10 12 genomic copies per kilogram (gc kg À 1 ) was needed to provide a therapeutic correction. This dose seems significantly higher than the 5 Â 10 11 vp kg
) of AdV needed for complete correction. The requirement of an increased number of vector copies for therapeutic correction could be a potential disadvantage with respect to long-term safety. Although, the absence of active integration precludes the risk for insertional mutagenesis to a large extent, random integration of both vectors does occur in the presence of double-strand breaks. The integration frequency will depend on the number of double-strand breaks and the amount of vector genomes available. A lower number of vector genomes required for therapeutic efficacy therefore seems an advantage.
As a direct comparison of the efficacy of both vectors in a relevant disease model is lacking, the aim of this study is to compare them in the Gunn rat using doses that are 1 Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands and applicable in patients. The efficacy of AdV serotype 5 is compared with that of double-stranded or self-complimentary AAV (scAAV) reported to have a higher liver transduction efficacy than the single-stranded (ssAAV) vector. 16 We chose AAV serotype 1, shown to provide the highest correction in the Gunn rat in our previous study, and AAV serotype 8, successfully applied in patients suffering from hemophilia B.
14 Due to the different titration methods comparing their efficacy based on the vector dose needed is not valid. Therefore, the number of vector genomes present in the liver required for correction of hyperbilirubinemia is used instead. To allow such a direct comparison, identical UGT1A1 expression cassettes are present in both vectors. The results indicate that although the UGT1A1 mRNA levels expressed by both vectors are comparable, a lower number of AdV genomes is needed for therapeutic efficacy. Flanking the expression cassette with AAV-ITRs (inverted terminal repeats) resulted in an eightfold increase of UGT1A1 mRNA expressed per AdV genome and a more effective vector.
RESULTS
In AAV, but not in AdV, the cytomegalovirus (CMV) promoter provides sustained UGT1A1 expression in the liver Systemic injection of ssAAV-CMV-UGT1A1 provides life-long correction of hyperbilirubinemia in the Gunn rat. 15 To investigate the efficacy of the same expression cassette in combination with AdV delivery, Ad-CMV-UGT1A1 was injected into the tail vein of Gunn rats. A single injection of Ad-CMV-UGT1A1 (3 Â 10 10 infectious particles per kg (ip kg À 1 ) resulted in a complete correction of serum bilirubin levels in the Gunn rats ( Figure 1a ). In these rats, 2-3 weeks after the injection serum bilirubin started to rise reaching pre-injection control levels after 6-8 weeks. Tail vein injection of 6.7 Â 10 10 ip kg À 1 of Ad-CMVUGT1A1inv, containing the CMV-UGT1A1 in the inverted orientation, also resulted in a complete but transient correction of serum bilirubin levels (not shown). As reported previously, and in contrast to AdV, a lifetime correction was obtained with this expression cassette upon AAV-mediated delivery. 15 The transient character of AdV-mediated correction is very similar to that reported in other studies with first-generation AdV vectors in this animal model. 17 This loss of correction does not result from the complete disappearance of all vector genomes from the liver. At 16 weeks, the presence of AdV genomes is 0.126±0.012 copies/diploid rat Genome (dGE) (n ¼ 4), suggesting that the loss of efficacy (in part) is due to silencing of the CMV promoter. The CMV promoter-driven expression induces a strong humoral immune response towards UGT1A1 (Figure 1b) . This is comparable to that seen with AAV1-CMV-UGT1A1. 15 To investigate whether this response has a role in the loss of correction, 3 months after the first injection with Ad-CMV-UGT1A1 two rats were injected via the tail vein with scAAV8-CMV-UGT1A1. This results in a partial but sustained correction of serum bilirubin levels (Figure 1a) , indicating that the presence of a pre-existing humoral response against UGT1A1 does not prevent AAV-mediated expression in the liver, rendering it unlikely that these humoral immune responses are the cause of the rapid loss of correction seen with these AdV vectors.
Compared with AAV, AdV delivery of a liver-specific expression cassette provides more efficient correction of hyperbilirubinemia The life-long correction provided by AAV-CMV-UGT1A1 indicates that the transient correction seen with Ad-CMV-UGT1A1 must be due to the expression of AdV proteins. Use of a constitutive promoter like CMV will result in the expression of AdV proteins in many tissues, including antigen-presenting cells, thereby increasing the adaptive immune response. 18 Restricting the expression of therapeutic and AdV proteins to hepatocytes will reduce this problem. To this end, the CMV promoter was replaced by the hepatocyte-specific LP1 promoter. 16 In addition to the forward orientation, the liver-specific expression cassette was inserted in the inverse orientation to eliminate the potential expression of AdV proteins from the LP1 promoter, for instance, due to aberrant splicing. 19 In the Gunn rat, the efficacy of the resulting vectors Ad-LP1-UGT1A1 and Ad-LP1-UGT1A1inv is compared with that of scAAV1-LP1-UGT1A1 and with that of scAAV8-LP1-UGT1A1. Tail vein injection of a dose 3 Â 10 10 ip kg À 1 of Ad-LP1-UGT1A1inv normalizes serum bilirubin levels ( Figure 2a ). Even a threefold lower dose of this vector (1 Â 10 10 ip kg À 1 (4.7 Â 10 11 vp kg
)) does provide a sustained 90% reduction of serum bilirubin levels. The correction provided by the same dose of Ad-LP1-UGT1A1 was significantly less, which appeared to be due to a lower number of vector copies persisting in the liver ( Figure 4 ). Tail vein injection of a medium dose of scAAV1-LP1-UGT1A1 of 3 Â 10 11 gc kg À 1 results in a 40% reduction of serum bilirubin levels only (not shown). To obtain the same extend of correction as provided by AdV, this scAAV1 vector has to be injected into the portal vein, and the vector dose has to be increased to 1 Â 10 12 gc kg À 1 ( Figure 2b ). To investigate whether this higher dose of AAV1 also results in a comparable presence of UGT1A1-expressing hepatocytes, immunohistochemistry was performed using sections of snap-frozen liver ( Figure 3 ). This revealed that the number of positive cells increased upon injection of higher doses of scAAV1. At the highest dose of scAAV1, the presence of UGT1A1-expressing hepatocytes seems comparable to that in rats injected with Ad-LP1-UGT1A1inv and higher than with Ad-LP1-UGT1A1. This and the comparable Table 1 ). Several studies in mice have demonstrated that AAV8 is more efficient for liver transduction than AAV1. 20 Therefore, the efficacy of this serotype containing the same expression cassette was also investigated in the Gunn rat. Portal vein injection of the medium dose of 3 Â 10 11 gc kg À 1 of scAAV8-LP1-UGT1A1 indeed appeared more effective than the same dose of AAV-1, but the increase in efficacy was small compared with the 410-fold increase reported in mice (Figure 2b ).
To investigate whether these doses result in the delivery of a comparable amount of vector genomes to the liver, the transgene copy number was determined using quantitative real-time PCR. The ratio between the copy number of the hUGT1A1 and that of the endogenous rat b-actin gene Â 2 is taken as the vector copy number per diploid rat genome (vc/dGE). As shown in Figure 4 , the more efficient correction provided by the medium dose of scAAV8 compared with the same dose of scAAV1 seems to result from a higher number of vector copies delivered to the liver (P ¼ 0.05). In contrast, the significant increased efficacy of AdV is not accompanied by an increased number of vector copies (Figure 4 ). These data indicate that a higher number of AAV vector copies are needed to reach the level of correction provided by AdV. Except for the flanking ITRs, which are only present in AAV, both vectors contain identical expression cassettes. To investigate a potential effect of these ITRs on the vector efficacy, an AdV vector containing the entire AAV construct, including the 5 0 and 3 0 ITR, was generated. ) of Ad-AAV-LP1-UGT1A1 resulted in a 495% reduction of serum bilirubin levels ( Figure 5 ). This complete correction persisted until the end of the experiment, and serum bilirubin levels remained very low after 48 weeks, whereas in control animals serum bilirubin levels show a gradual increase in time. This suggests that the LP1 promoter-driven expression of UGT1A1 is increased by flanking it by AAV2 ITRs. The eightfold higher UGT1A1 mRNA level in the liver per vector copy confirms that its expression is indeed enhanced in this hybrid vector ( Figure 6 ).
DISCUSSION
In a relevant animal model, the Gunn rat, AdV and AAV vectors both provide effective and prolonged correction of the severe unconjugated hyperbilirubinemia, characteristic of Crigler-Najjar syndrome type 1. 11,15 Its lower immunogenicity renders AAV of these two the best option for treating inherited liver disorders. The recent successful treatment of several patients suffering from hemophila B indeed underscores the potential of this vector. 14 However, the larger cloning capacity of AdV vectors can still be an important advantage when aiming to correct diseases caused by mutations in larger genes, such as those in the factor VIII gene causing hemophilia A. In addition, a higher vector efficacy seems another advantage as it will reduce the number of vector genomes required for efficient correction, thereby lowering the presence of genomes available for integration. As a direct comparison between AdV and AAV was lacking, the aim of this study was to compare their efficacy in Gunn rats.
In a previous study, we have shown that ssAAV1-CMV-UGT1A1 provides life-long correction in the Gunn rat. 15 Inserting this expression cassette into an AdV vector did provide efficient and complete but short-lived correction (Figure 1 ). This transient nature is similar to that seen by other groups. 10, 21 It is caused by adaptive immune responses towards AdV proteins. 22, 23 In contrast to the study of Li et al., 21 we found continued presence of the UGT1A1 transgene in the liver. An important difference between both studies is the detection method used. The sensitive quantitative PCR (qPCR) used here does allow detection and quantification of low transgene levels. It shows that although the expression was lost, the level of Ad-CMV-UGT1A1 copies remaining in the liver was comparable to that of Ad-LP1-UGT1A1 in rats with persisting correction. The persistence of vector genomes while the correction is lost does suggest the loss of UGT1A1 expression, at least in part, is due to silencing of the CMV promoter. Transcriptional silencing of this promoter has also been reported upon AdV gene delivery to the muscle. 24 The sustained correction of serum bilirubin provided by AAV-CMV-UGT1A1 seen in our previous study and in this study in rats first injected with Ad-CMV-UGT1A1, demonstrates this silencing is vector dependent. In this respect, the recent study of the group of Wilson showing that inflammation can prevent prolonged expression seems very relevant. 25 Although in that study some loss corrected cells was seen, silencing of transgene expression due to the inflammatory response appeared to be the main cause of the loss of correction. The mild and transient increase in liver enzymes observed a week after injection of Adenovirus, would be in agreement with such a mechanism (not shown). Furthermore, the prolonged expression of hUGT1A1 upon injection of AAV-CMV-UGT1A1 in two rats initially injected with Ad-CMV-UGT1A1 demonstrates the absence of an (efficient) cellular immune response against hepatocytes expressing this human protein.
The strength of the promoter driving the transgene expression has a pivotal role in the expression of the AdV proteins, such as protein IX, and thus in the induction of adaptive immune responses and inflammation. 18, 19 Using the weaker but liverspecific LP1 promoter reduces this expression and limits it to hepatocytes. This results in sustained correction. Inserting the LP1-driven expression cassette in the inverse orientation further increases the efficacy of the AdV. The difference in efficacy between these two AdV vectors seems not to be caused by a difference in transcriptional activity as both have comparable levels of UGT1A1 mRNA/vector genome ( Figure 6) . Instead it appears due to a lower number of Ad-LP-UGT1A1 vector copies persisting in the liver (Figures 3 and 4) . A possible explanation for this difference is that the expression of AdV genes in Ad-LP1-UGT1A1inv is reduced compared with that in Ad-LP1-UGT1A1. This would limit the loss of transduced cells due to an adaptive immune response. At the time of killing, no expression of AdV genes was detectable in these animals. The sustained and stable correction of serum bilirubin obtained with these two firstgeneration vectors, however, do indicate that this effect is small. Importantly, these data do demonstrate that these liver-specific first-generation AdV vectors can provide sustained correction in this naive animal model. Prolonged expression with first-generation liver-specific AdV vectors has been reported previously, for instance, in a mouse model for AAT deficiency and of hGH in C57BL/6 mice. 19, 26 In the human situation, however, the presence of a memory response against AdV proteins may result in a more rapid and more potent immune response. The higher efficacy of a HD-Ad compared with a liver-specific first-generation AdV vector in an immune competent mouse model suggest that this mechanism also occurs in a naive animal model, albeit to a lesser extent. 26 Application of gutless HDAd will exclude this risk and therefore seems preferable for clinical use.
In addition to a sustained correction, these liver-specific Ad-LP1-UGT1A1 and Ad-LP1-UGT1A1inv also appeared very efficient. Injection of 3 Â 10 10 ip kg À 1 resulted in normalization of serum bilirubin levels, whereas a dose of 2 Â 10 12 gc kg À 1 of scAAV1-LP1-UGT1A1 was needed to provide a comparable correction based of serum bilirubin, amount of bilirubin glucuronides in bile and UGT1A1-expressing hepatocytes (Figures 2 and 3 and Table 1 ). The high dose of portal vein-injected scAAV1 needed for complete correction is also reflected by the significant increase of the UGT1A1 transgene levels in the liver compared with those receiving the AdV (P ¼ 0.02). Genomic copies in the livers of rats injected with the medium scAAV1 dose are similar to those seen in rats treated with the high dose of AdV, but the correction of serum bilirubin is significantly better with the latter. As reported for mice, scAAV8 also appeared more effective in the Gunn rat although the difference was small (Figure 2b ). This increased efficacy was accompanied by an increase of UGT1A1-expressing hepatocytes ).
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and a 60% increase in vector genomes in the liver (Figures 3 and 4) . However, both AAV vectors did not reach the level of correction seen with AdV vectors. Together these findings indicate that compared with AdV an increased number of AAV-delivered transgenes are needed to obtain the same level of correction. This significant difference in efficacy is not due to the UGT1A1 expression level provided by both vectors. The identical UGT1A1 expression cassette resulted in a similar UGT1A1 mRNA level per vector genome ( Figure 6 ). A possible explanation for the difference in efficacy could be that AAV forms large concatamers, which leads to the presence of a high number of vector genomes in a limited number of cells. This would result in a very high UGT1A1 expression in a small percentage of the hepatocytes. In these cells, other steps of bilirubin metabolism, such as its uptake or the availability of UDPGA, may become limiting. This will result in a lower efficacy. To investigate this, immuno-histochemical stainings were performed in all treated animals. However, due to the variation in the staining intensity, most likely due to the difference in UGT1A1 expression between hepatocytes, a reliable quantification of the percentages of UGT1A1-positive hepatocytes was not possible. Another possible explanation would be that the AAV ITRs flanking the expression cassette in AAV affect UGT1A1 expression. To investigate this, an AdV vector with both ITRs flanking the expression construct was generated. This hybrid AdV vector appeared even more efficient than Ad-LP1-UGT1A1inv providing complete correction of serum bilirubin levels at a lower vector dose. This increased efficacy was not due to a more efficient delivery of transgenes to the liver as both established similar UGT1A1 transgene levels ( Figure 4 ). The main difference between this hybrid AdV and both other AdV was the UGT1A1 expression level. In rats treated with the hybrid vector, the UGT1A1 mRNA level per vector genome in the liver is eightfold higher. This indicates that flanking of the expression cassette by the AAV ITRs does increase the activity of the LP1 promoter. This may be due to the transcriptional activity of the A/D element present in these ITRs. 27 An increased transcriptional activity in vivo upon insertion of ITRs is in agreement with studies of AAV and AAV hybrid vectors based on Herpes Simplex Virus and Baculo Virus. [28] [29] [30] The UGT1A1 mRNA expression by this AdV hybrid vector is also higher than that of the two AAV vectors that contain these ITRs. The formation of large concatamers by AAV in the liver Abbreviations: BDG, bilirubin di-glucuronide; BMG, bilirubin monoglucuronide; gc, genomic copies; ip, infectious particle; ND, not determined; UCB, unconjugated bilirubin. Bile was sampled at the time of killing 48 weeks after vector injection and analyzed for the presence of UCB, BMG and bilirubin di-glucuronide. The data represent individual animals and refer to the percentage of the total amount of bilirubin present in bile. could also explain the lower UGT1A1 expression provided by both scAAV vectors compared to the hybrid AdV. This conversion may result in the presence of incomplete genomes that lack the promoter or poly A or due to the presence of many genomes transcription factors may become limiting. Both the presence of inactive genomic copies or limiting transcription factors levels will lower the mRNA/vector copy ratio. As the aim of this study was to compare the efficacy of clinically relevant doses of both vectors, the amount of vector genomes delivered to the liver was too low to further analyze their structures in the liver. Another more trivial explanation would be that the gc levels of the hybrid vector are underestimated due to the presence of the AAV ITRs. 31 However, as the distance between the amplicon and the AAV hairpin is about 800 bp such an effect will be small while the expression levels differ with a factor of 8. Furthermore, cutting the total genomic liver DNA extensively with EcoR1, the sites of which are located between both ITRs and the amplicon, does not result in higher gc levels (not shown). Altogether this indicated that flanking the expression cassette with AAV ITRs does increase the expression most likely by enhancing the transcription activity of the LP1 promoter.
In conclusion, we have generated liver-specific first-generation AdV vectors that in contrast to earlier studies do provide sustained correction of hyperbilirubinemia in the Gunn rat. The efficacy of these AdV appeared higher than that of double-stranded scAAV serotypes 1 and 8, based on serum bilirubin level and a lower number of vector genomes in the liver required for complete correction. This increased efficacy is not caused by a difference in UGT1A1 expression per vector genome. Flanking the expression cassette in AdV with AAV2 ITRs does enhance the UGT1A1 mRNA expression in the liver provided by this vector. The efficacy of this hybrid vector is further increased, which allows additional dose reduction that seems essential for lowering the risk of adverse immune responses against AdV.
MATERIAL AND METHODS

Construction and production of viral vectors
To generate Ad-CMV-UGT1A1, the cDNA encoding human UGT1A1 was extracted from pSVK3. 32 For the Ad-LP1-UGT1A1 vectors, the entire expression cassette, including the SV40 poly-adenylation sequence, was isolated from scAAV-LP1-UGT1A1, 33 while for the Ad-AAV-LP1-UGT1A1, this expression cassette including the flanking AAV2 ITR was extracted. All constructs were cloned into pShuttle and sequenced to exclude mutations. Adenoviruses were generated using recombination with the AdEasy I vector. 34 A scheme of the AdV vectors used is given in Supplementary Figure S1 . AdV vectors were produced on 293T cells using the standard protocols and titrated using the rapid titration assay giving ip and OD280 nm giving vector particles (vp). 35 The respective titers were: 1. ) for Ad-AAV-LP1-UGT1A1. All AAV vectors were produced, purified and titered as described. 15 
Animal experiments
All animal experiments were performed in accordance with the Animal Ethical Committee guidelines of the Academic Medical Center of Amsterdam and guidelines for animal welfare from the French Ministè re de l 0 Agriculture. Male Gunn rats from our own colonies, 8-10 weeks of age, weighing between 180 and 200 g, were fed ad libitum and randomly assigned to the different treatment groups. AAV vectors were injected via the portal vein or tail vein, while all AdV vectors were injected via the tail vein. Portal injections, blood sampling and bile collection were performed as described previously. 15 Immunohistochemical staining Snap-frozen liver slices 5 mm were dried at room temperature (RT), fixated for 10 min in aceton, dried again and washed three times in phosphatebuffered saline (PBS). Endogenous peroxidase activity was blocked by incubating for 1 h in (0.1% sodium-azide, 40% methanol and 0.3% H 2 O 2 ). After three washes with PBS aspecific staining was blocked by a 10 min incubation in Ultra V block (Thermo Scientific, Waltham, MA, USA) and a 15 min incubation with Avidin followed by three washes with PBS. The slides were incubated o/n with a rabbit anti-human UGT1A1, diluted 1:10 000 in TENGT þ 10% normal goat serum (NGS). The next day the slides were washed three times with PBS and incubated for 10 min with bio goat antirabbit (E0432 DAKO, Glostrup, Denmark) diluted 1:400 in TengT with 10% NGS. After three washes with PBS the slides were incubated for 10 min with LSAB2-streptavidin-horseradish peroxidase (K1016 DAKO), washed again three times with PBS and incubated with nova red (Nova Red Kit SK-4800; Vector Laboratories Inc, Burlingame, CA, USA) for 40 min. All incubations were at RT.
DNA and RNA analysis A hundred nanograms of genomic DNA, isolated according to the Y procedure, 36 was used to determine the UGT1A1 gene copy number by qPCR in the Roche LightCycler480 with the fast-start SYBRgreen kit (Mannheim, Germany) using these primers fw: 5 0 -GACGCCTCGTTGTACA TCAG-3 0 and rv: 5 0 -CACGCTGCAGGAAAGAATC-3 0 . Dilutions of UGT1A1 plasmid into rat genomic DNA and normalizing to the endogenous rat b-actin gene amplified using the primers fw: 5 0 -AGCCATGTACGTAGCCAT CCA-3 0 and rv: 5 0 -TCTCCGGAGTCCATCACAATG-3 0 were used to generate the standard curves. To determine the expression of the UGT1A1 gene, total liver RNA was isolated using Trizol and 1 mg was used for cDNA synthesis using oligo-dT and a primer for 18S and Superscript 3. qPCR was performed using the same primers for UGT1A1 as used to determine genomic copies and primers for 18S (fw: 5 0 -CGAACCTCCGACTTTCGTTCT-3 0 ; rv: 5 0 -TTCGGAACTGAGGCCATGAT-3 0 ). vc/dGE and UGT1A1 mRNA/18S were calculated using the LinRegPCR software (AMC, Amsterdam). 37 
Bilirubin quantification
Total bilirubin in serum was determined by the routine clinical chemistry department using a standard colorimetric assay (Roche Diagnostics, Almere, The Netherlands). Unconjugated bilirubin and bilirubin conjugates in the bile were analyzed and quantified by high-performance liquid chromatography as described 15 with the modification that a pursuit column (Agilent, Amstelveen, The Netherlands) was used. 33 
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